Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by Schaffhausenon Feb 24, 2016 10:35pm
308 Views
Post# 24592575

Anatomy of a Takeover

Anatomy of a TakeoverThe anatomy of a takeover includes management buy-in as a prerequisite.  I have seen these transactions occur from a front row seat.  A company is only as saleable as the management cooperates to be bought out.  At face value the design of the Nuvo company split is based on management enrichment that will occur in a friendly takeover and then also by continued custody and control of the cash reserves through Crescita (while also within arms reach of the compensation scheme). 

It would not be a lofty test to prove the risky and non-investment grade nature of the Crescita "business" plan.  The salient question becomes:  If high risk non-investment grade decisions are supported by the BOD, then what is left of FIDUCIARY duty?  Are shareholders expected to relinquish their invested dollars to the equivalent of a lottery "business plan" ?  Is it democratic or oppresive to put the business plan up to a kangaroo court vote where management uses the shareholders very own invested dollars to persuade less sophisticated  and apathetic shareholders to vote in their favour?  How many voting shares are closely held?  How many brokers were acting faithfully in their clients interests by advising a "YES" vote considering that the Crescita business plan doesn't describe any return potential beyond what might be expected playing KENO?

An eventual takeover of NRI will simply corroborate the contrived scheme and add to the weight of evidence.  What's interesting is that the BOD may find that, in the event of a buyout of NRI at any multiple of todays shareprice, there will be many well funded plaintiffs from the "offended" ownership pool.  Sometimes its not all about money, it can become personal.  It would certainly behoove my jurisprudent sensibilities to play this out in her majesty's court of law.  Within those four walls the BOD loses their cloak of invincibility; it only takes one rational thinker with a refined BS sniffer to bring justice.

Cheers,

Schaff

Schaff

 
Bullboard Posts